PMID- 25709459
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150224
LR  - 20201001
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 11
DP  - 2015
TI  - The noradrenaline metabolite MHPG is a candidate biomarker between the 
      depressive, remission, and manic states in bipolar disorder I: two long-term 
      naturalistic case reports.
PG  - 353-8
LID - 10.2147/NDT.S74550 [doi]
AB  - BACKGROUND: Treatment of the depressive and manic states in bipolar disorder I 
      (BDI) is a challenge for psychiatrists. Despite the recognized importance of the 
      switch phenomenon, the precise mechanisms underlying this process are yet to be 
      shown. We conducted a naturalistic study in two BDI patients to determine whether 
      biological markers (monoamine metabolites and brain-derived neurotrophic factor 
      [BDNF]) are associated with the switch between depressive and manic states. CASE 
      PRESENTATION AND METHODS: Blood sampling and mood assessments were performed at 
      2-week intervals over a period of 2 (Case 1, n=72) and 6 (Case 2, n=183) years. 
      Plasma concentrations of 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic 
      acid (HVA) were analyzed by high-performance liquid chromatography with 
      electrochemical detection. Plasma BDNF was assayed by sandwich ELISA 
      (enzyme-linked immunosorbent assay). RESULTS: MHPG had the highest standardized 
      coefficient (beta) in the multiple regression analysis. We found a significant 
      positive correlation between Young Mania Rating Scale scores and plasma MHPG 
      levels (Case 1: rho=0.429; Case 2: rho=0.488), and a significant negative correlation 
      between Montgomery-Asberg Depression Rating Scale scores and MHPG levels (Case 1: 
      rho=-0.542; Case 2: rho=-0.465). Conversely, no significant correlation was found 
      between the level of BDNF and the presence of a manic or depressive state, and 
      although HVA had a slightly stronger correlation than MHPG, the levels of neither 
      of these were found to significantly correlate with the symptoms. CONCLUSION: 
      These data suggest that peripheral MHPG levels (which is related to noradrenaline 
      levels in the brain) could be used as a biomarker of mood states in BDI. The 
      noradrenaline level in the brain is likely to reflect the clinical 
      characteristics of the switch process in BDI, and has prognostic significance for 
      the treatment of both manic and depressive states.
FAU - Kurita, Masatake
AU  - Kurita M
AD  - Sato Hospital, Koutokukai, Nanyo, Yamagata, Japan ; Department of Cellular 
      Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 
      Miyagi, Japan ; Department of Psychiatry and Behavioral Science, Graduate School 
      of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
FAU - Nishino, Satoshi
AU  - Nishino S
AD  - Sato Hospital, Koutokukai, Nanyo, Yamagata, Japan ; Department of Cellular 
      Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 
      Miyagi, Japan.
FAU - Numata, Yukio
AU  - Numata Y
AD  - Sato Hospital, Koutokukai, Nanyo, Yamagata, Japan.
FAU - Okubo, Yoshiro
AU  - Okubo Y
AD  - Department of Psychiatry and Behavioral Science, Graduate School of Medicine, 
      Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
FAU - Sato, Tadahiro
AU  - Sato T
AD  - Sato Hospital, Koutokukai, Nanyo, Yamagata, Japan.
LA  - eng
PT  - Journal Article
DEP - 20150211
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4334324
OTO - NOTNLM
OT  - brain-derived neurotrophic factor (BDNF)
OT  - depression
OT  - dopamine
OT  - homovanilic acid (HVA)
OT  - monoamine
OT  - mood disorder
OT  - pathophysiology
EDAT- 2015/02/25 06:00
MHDA- 2015/02/25 06:01
PMCR- 2015/02/11
CRDT- 2015/02/25 06:00
PHST- 2015/02/25 06:00 [entrez]
PHST- 2015/02/25 06:00 [pubmed]
PHST- 2015/02/25 06:01 [medline]
PHST- 2015/02/11 00:00 [pmc-release]
AID - ndt-11-353 [pii]
AID - 10.2147/NDT.S74550 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2015 Feb 11;11:353-8. doi: 10.2147/NDT.S74550. 
      eCollection 2015.